Please ensure Javascript is enabled for purposes of website accessibility

United Therapeutics’ earnings soar

United Therapeutics Corp., of Silver Spring, a specialty drug maker that develops and markets treatments for unmet medical needs of patients with chronic and life-threatening conditions, reported first-quarter net income totaled $137.5 million, or $2.43 per diluted share, an increase of more than 120 percent compared to the $62.3 million, or $1.19 per diluted share, reported in the prior-year period.

Revenue was $289.4 million, 18 percent higher than the $245.1 million posted in the first quarter of 2013.

Analysts polled by Thomson Reuters forecast, on average, earnings of $1.65 per share on revenue of $300.14 million.

UTC attributed the surge in earnings to more people using its products, including a medicine to treat pulmonary arterial hypertension.